Methylene blue in cardiogenic shock and cardiac arrest: A systematic review. (2025)

Peer-Reviewed Study · Batchelor RJ, Watkins M, Bloom JE, Lankaputhra M, Chew DP, Burrell A, Taylor A, Stub D, Kaye DM · September 9, 2025

Batchelor RJ et al., 2025-09-09: Systematic review finding almost no human data on methylene blue in cardiogenic shock or cardiac arrest, with benefit in older animal models but minimal or no benefit in newer bolus-only infarct models.

This systematic review highlights the lack of data available for MB in cardiogenic shock and cardiac arrest, especially in humans.

Batchelor RJ et al., 2025-09-09: Systematic review finding almost no human data on methylene blue in cardiogenic shock or cardiac arrest, with benefit in older animal models but minimal or no benefit in newer bolus-only infarct models. C5 (evidence-gap finding). Study type: systematic review, MEDLINE/Embase/CENTRAL/Scopus/Web of Science searched March 2025; Alfred Health, Melbourne, Australia. The single human study lacked a comparator group. Funding/conflicts: author support from an NHMRC Postgraduate Scholarship and NHF funding per the acknowledgements field. Methylene blue dose not applicable. Bearing PARTLY: no human efficacy evidence, and animal results conflict by model. Shock 2025 (volume/pages not in the abstract). Study type: review.